Effects of glucocorticoids and methotrexate-based therapeutic regimens on B cell subpopulations in patients with IgG4-related disease.

Marco Lanzillotta\textsuperscript{1,2}, Emanuel Della-Torre\textsuperscript{3}, Raffaella Milani\textsuperscript{2}, Enrica Bozzolo\textsuperscript{2}, Emanuele Bozzalla Cassione\textsuperscript{2}, Lucrezia Rovati\textsuperscript{2}, Massimo Falconi\textsuperscript{2}, Paolo Giorgio Arcidiacono\textsuperscript{2}, Lorenzo Dagna\textsuperscript{2}.

1. Università Vita Salute San Raffaele, Unit of Immunology, Rheumatology, Allergy and Rare Diseases - San Raffaele Scientific Institute
2. San Raffaele Scientific Institute

Objective:
IgG4-related disease (IgG4-RD) is a systemic fibro-inflammatory disorder characterized by fibrotic lesions infiltrated by IgG4 positive plasma cells. The prompt clinical responses obtained after B cell depletion with rituximab in IgG4-RD patients suggest that B lymphocytes drive the pathogenesis of this condition and sustain disease activity. This conclusion, however, requires further confirmation because IgG4-RD responds also to non-B cell depleting therapies such as glucocorticoids and methotrexate. In the present work we aim to evaluate the effects of glucocorticoids and methotrexate-based therapeutic regimens on B lymphocyte subpopulations in patients with IgG4-RD.

Methods:
Sixteen patients with active IgG4-RD were studied. FACS analysis on PBMCs was performed in order to identify the following B cell subpopulations: total B cells (CD19+CD20- and CD19+CD20+ cells), circulating plasmablasts (CD19+CD20- CD27+CD38+ cells), naive B cells (CD19+CD20+CD27-CD38+ cells), memory B cells (CD19+CD20- CD27+CD38+ cells), circulating plasma cells (CD38+CD138+ cells). Disease activity was assessed by means of the IgG4-RD responder index (IgG4-RD RI). Flow cytometry was performed at baseline and after six months of immunosuppressive therapy with glucocorticoids (0.6-1mg/kg/day) and/or methotrexate (10-20mg/week). Ten sex and age matched healthy subjects were used as controls.

Results:
At baseline, circulating plasmablasts were expanded in IgG4-RD patients (median 3780 cell/mL; range 330-9300) compared to controls (median 280 cell/mL; range 0-1000) \((p<0.05)\); total B cells (median 133000 cell/mL; range 34000-569000) and naive B cells (median 13080 cell/mL; range 1970-64270) were reduced in IgG4-RD patients compared to controls (median 280 cell/mL; range 194-330; and median 54020 cell/mL; range 21050-106780, respectively) \((p<0.05)\). No differences in memory B cells and circulating plasma cells were observed \((p>0.05)\). Circulating plasmablasts but not other B cell subsets positively correlated with serum IgG4 levels, number of organ involved, and IgG4-RD RI \((p<0.05)\). At six months follow-up, the median IgG4-RD RI decreased from 9 to 2. Circulating plasmablasts and naive B cells counts decreased in all patients together with disease improvement \((p = 0.0002 \text{ and } 0.025 \text{ compared to baseline values, respectively})\); total B cells, circulating plasma cells, and memory B cells were unaffected by immunosuppressive therapy.

Conclusions:
Non-B cell depleting therapies based on glucocorticoids and/or methotrexate induce clinical improvement and deplete circulating plasmablasts and naive B cells in patients with IgG4-RD; circulating plasma cells and memory B cells are not affected by glucocorticoids and methotrexate. Our study, performed with non-B cell depleting agents, provides clinical evidences that circulating plasmablasts are likely linked to IgG4-RD pathogenesis and disease activity.